Tolerability of the compound ABHR in hospice patients

Journal of Palliative Medicine

Volumn 8, Issue 6, 2005, Pages 1135-1143

  Weschules, Douglas J ^a  

^a excelleRx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABHR; DIPHENHYDRAMINE; HALOPERIDOL; LORAZEPAM; METOCLOPRAMIDE;

ADULT; AGE; AGED; AGITATION; ALLERGIC REACTION; ANTICHOLINERGIC SYNDROME; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; CONFUSION; CONSTIPATION; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FLUSHING; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; GEL; HALLUCINATION; HEART PALPITATION; HICCUP; HOME CARE; HOSPICE CARE; HUMAN; HYPOTENSION; INCREASED AGITATION; LETHARGY; MAJOR CLINICAL STUDY; NAUSEA; NIGHTMARE; PRESCRIPTION; RESTLESSNESS; RETROSPECTIVE STUDY; SEDATION; SIDE EFFECT; SOMNOLENCE; TREMOR; UNITED STATES; URTICARIA; VOMITING; WEIRD SENSATION;

AGED; ANTIEMETICS; COHORT STUDIES; DIPHENHYDRAMINE; DRUG COMBINATIONS; FEMALE; HALOPERIDOL; HOSPICE CARE; HUMANS; LORAZEPAM; MALE; METOCLOPRAMIDE; NAUSEA; RETROSPECTIVE STUDIES; UNITED STATES; VOMITING;

EID: 29444444396     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2005.8.1135     Document Type: Article

References (40)

1. Reuben DB, Mor V: Nausea and vomiting in terminal cancer patients. Arch Intern Med 1986;146(10):2021-2023.
2. McMillan SC, Small BJ: Symptom distress and quality of life in patients with cancer newly admitted to hospice home care. Oncol Nurs Forum 2002;26: 1421-1428.
3. Grant M: Nausea and vomiting, quality of life, and the oncology nurse. Oncol Nurs Forum 1997;24:5-7.
4. Grond S, Zech D, Diefenbach C, Bischoff A: Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 1994;9:372-382.
5. Fainsinger R, Miller MJ, Bruera E, Hanson J, Maceachern T: Symptom control during the last week of life on a palliative care unit. J Palliat Care 1991;7(1):5-11.
6. Bruera E, Sweeney C: Chronic nausea and vomiting. In: Berger AM, Portenoy RK, Weissman DE (eds): Principles and Practice of Palliative Care and Supportive Oncology, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002, pp. 222-232.
7. Muir JC, von Gunten CF: Abdominal cancer, nausea, and vomiting. J Palliat Med 2001;4:391-394.
8. Kris MG, Gralla RJ, Tyson LB, Clark RA, Kelsen DP, Reilly LK, Groshen S, Bosl GJ, Kalman LA: Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine. Cancer 1985;55:527-534.
9. Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S: Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. Cancer 1987;60:2816-2822.
10. Sridhar KS, Donnelly E: Combination antiemetics for cisplatin chemotherapy. Cancer 1988;61:1508-1517.
11. Sridhar KS, Hussein AM, Hilsenbeck S, Cairns V: Five-drug antiemetic combination for cisplatin chemotherapy. Cancer Invest 1992;10:191-199.
12. Roila F, Tonato M, Basurto C, Picciafuoco M, Bracarda S, Donati D, Malcarne P, Monici L, Di Costanzo F, Patoia L, et al: Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine. A study of the Italian Oncology Group For Clinical Research. J Clin Oncol 1989;7: 1693-1700.
13. Roila F, Basurto C, Bracarda S, Picciafuoco M, Ballatori E, Del Favero A, Tonato M: A pilot study of metoclopramide, dexamethasone, diphenhydramine and lorazepam in prevention of nausea and vomiting in cisplatin-treated male patients. Oncology 1990;47:415-417.
14. Roila F: Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination. Oncology 1993;50:163-167.
15. The Italian Group For Antiemetic Research: Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 1992;340:96-99.
16. The Italian Group For Antiemetic Research: Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993;11:2396-2404.
17. Navarri RM, Province WS, Perrine GM, Kilgore JR: Comparison of intermittent ondansetron versus continuous infusion metoclorpamide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. Cancer 1993;72:583-586.
18. O'Brien MER, Cullen MH, Woodroffe C, Kelly K, Burman C, Palmer K, Stuart NS, Blackledge GR, Sharpe J: The role of metoclopramide in acute and delayed chemotherapy induced emesis: A randomised double blind trial. Br J Cancer 1989;60:759-763.
19. Ballatori E, Roila F, Berto P, De Angelis V, Neri C, Oliveri A, Tonato M, Del Favero A: Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: A hospital perspective from Italy. Pharmacoeconomics 1994;5:227-237.
20. Cunningham D, Dicato M, Verweij J, Crombez R, de Mulder P, de Bois A, Stewart A, Smyth J, Selby P, van Straelen D, Parideans R, McQuade B, McRae J: Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: Ondansetron plus dexamethasone compated with metoclopramide, dexamethasone plus lorazepam. Ann Oncol 1996;7:277-282.
21. Sussman G, Shurman J, Creed MR, Larsen LS, Ferrer-Brechner T, Noll D, Allegra J, Montgomery R, Schreck D, Grafstein E, Ramalanjaona G, Patel V, Ducharmi J, Ortenwall P, Foster E, Ames M: Intravenous ondansetron for the control of opioid-induced nausea and vomiting: International S3AA3013 Study Group. Clin Ther 1999;12:1216-1227.
22. Buzdar AU, Esparza L, Natale R, Cody R, Calzone K, Benson AB 3rd, Sheehan T, Berry W: Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. Am J Clin Oncol 1994;17:417-421.
23. Lexi-Comp Online. Copyright © Lexi-Comp, Inc. 1978-2005. All rights reserved. Available from: http://www.lexi.com.
24. Davies A, Adena MA, Keks NA, Catts SV, Lambert T, Schweitzer I: Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther 1998;20:58-71.
25. Leucht S. Pitschel-Walz D, Kissling DA: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schiz Res 1999;35:51-68.
26. Schillevoort I, de Boer A, Herings RMC, Roos RAC, Jansen PAF, Leufkens HGM: Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother 2001;35:1517-1522.
27. Ayd FJ: Haloperidol: A new profile? Proc R Soc Med 1976;69:16.
28. Brockmöller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Müller-Oerlinghausen B, Roots I: The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002;72:438-452.
29. Vella-Brincat J, Macleod AD: Haloperidol in palliative care. Palliat Med 2004;18:195-201.
30. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS: Metoclopramdie: A review of its pharmacological properties and clinical use. Drugs 1976;12:81-131.
31. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC: Metoclopramide: An Updated Review of its Pharmacological Properties and Clinical Use. Drugs 1983;25:451-494.
32. Bright-Asare P, El-Bassoussi M: Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux. J Clin Gastroenterol 1980;2:149-156.
33. Miller LG, Jancovic J: Metoclopramide-induced movement disorders: Clinical findings with a review of the literature. Arch Intern Med 1989;149:2486-2492.
34. Lauterbach EC: Haloperidol-induced dystonia and parkinsonism on discontinuing metoclopramide: Implications for differential thalamocortical activity. J Clin Psychopharmacol 1992;12:442-443.
35. Schou H, Kongstad LL: Acute dystonia with fatal outcome. A possible adverse drug reaction in the simultaneous administration of chlorpromazine (Prozil) and metoclopramide (Primperan). Ugeskr Laeger 1986;148:2357-2358.
36. Factor SA, Matthews MK: Persistent extrapyramidal syndrome with dystonia and rigidity caused by combined metoclopramide and prochlorperazine therapy. South Med J 1991;84:626-628.
37. Eland IA, Belton KJ, van Grootheest AC, Meiners AP, Rawlins MD, Stricker BH: Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Pharmacol 1999;48:623-627.
38. Tolen L, McMath JA, Alt C, Weschules DJ, Knowlton CH, McPherson ML: Initial selection of anti-emetics in end-of-life care: A retrospective analysis. Presented as a poster at the 2005 Annual Assembly of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association, January 19-23, 2005. New Orleans, LA. Abstract available in J Palliat Med 2005:8(1):222.
39. Rousseau P: Antiemetic therapy in adults with terminal disease: A brief review. Am J Hospice Palliat Care 1995;12:13-18.
40. Miller KE, Miller M. Managing common gastrointestinal symptoms at the end of life. J Hospice Palliat Nursing 2002;4:34-12.